Company / Operating Cash Flow
Aclaris Therapeutics, Inc. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$47.1M
FY2025
5-year range
-$78.3M / -$47.1M
FY2021-FY2025
Trend
+39.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 9 years, ranging from -$101M in FY2020 to -$20M in FY2017.
Based on SEC 10-K filings.
-$47M in FY2025.
Improved from -$52M to -$47M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 39.8% year-over-year.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$47.1M | +39.8% |
| FY2024 | -$78.3M | -50.2% |
| FY2023 | -$52.1M | +22.8% |
| FY2022 | -$67.6M | -29.6% |
| FY2021 | -$52.1M | +48.3% |
| FY2020 | -$100.8M | -84.4% |
| FY2019 | -$54.7M | +45.8% |
| FY2018 | -$100.8M | -394.9% |
| FY2017 | -$20.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026